Drug intelligence / Profile preview

NMRA-CK1δ

Development stage: Preclinical
Lead developer: Neumora Therapeutics
Modality: Small Molecules

Overview

**NMRA-CK1δ** is a preclinical small molecule inhibitor of **casein kinase 1 delta (CK1δ)**, a serine/threonine kinase that regulates processes including DNA damage repair, circadian rhythm, cellular proliferation, and apoptosis. Developed by **Neumora Therapeutics**, it targets **tau hyperphosphorylation**, a pathological hallmark implicated in neurodegenerative diseases. The program is advancing for **amyotrophic lateral sclerosis (ALS)** and **Parkinson’s disease**, with preclinical data supporting its potential to address CK1δ dysfunction linked to these disorders[1][3][5][9].

Targets

CSNK1D (Casein kinase I delta)

Beyond the preview

Go deeper on NMRA-CK1δ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMRA-CK1δ.

Explore the full profile